摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

{[N-methyl-N-(2-hydroxyethyl)amino]carbonyl}-L-phenylalanine | 116129-72-7

中文名称
——
中文别名
——
英文名称
{[N-methyl-N-(2-hydroxyethyl)amino]carbonyl}-L-phenylalanine
英文别名
(2S)-2-[[2-hydroxyethyl(methyl)carbamoyl]amino]-3-phenylpropanoic acid
{[N-methyl-N-(2-hydroxyethyl)amino]carbonyl}-L-phenylalanine化学式
CAS
116129-72-7
化学式
C13H18N2O4
mdl
MFCD13493936
分子量
266.297
InChiKey
JIHCHEIWXMPQEL-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.384
  • 拓扑面积:
    89.9
  • 氢给体数:
    3
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    {[N-methyl-N-(2-hydroxyethyl)amino]carbonyl}-L-phenylalanine(2S)-N-[(2S,3S,5S)-1-cyclohexyl-3,5-dihydroxy-6-methylheptan-2-yl]-3-(1H-imidazol-5-yl)-2-(methylamino)propanamide1-羟基苯并三唑N,N'-二环己基碳二亚胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 (2S)-N-[(2S)-1-[[(2S,3S,5S)-1-cyclohexyl-3,5-dihydroxy-6-methylheptan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]-2-[[2-hydroxyethyl(methyl)carbamoyl]amino]-N-methyl-3-phenylpropanamide
    参考文献:
    名称:
    Novel Renin Inhibitors Containing (2S,3S,5S)-2-Amino-1-cyclohexyl-6-methyl-3,5-heptanediol Fragment as a Transition-state Mimic at the P1-P1' Cleavage Site.
    摘要:
    合成了一系列含有(2S, 3S, 5S)-2-氨基-1-环己基-6-甲基-3, 5-庚二醇(2-氨基-3, 5-反-二醇)片段作为新型过渡态模拟物的新型肾素抑制剂,并评价了它们的生物活性。所有在P1-P1'位置含有2-氨基-3, 5-反-二醇片段的合成化合物均表现出高体外肾素抑制活性,IC50值在10-8至10-10M范围内,并且大多数化合物在口服给盐缺乏的清醒狨猴时能降低血压。在P4位置含有4-羟基哌啶残基的抑制剂(29)在降低血压作用的强度和持续时间方面表现出最高的活性。
    DOI:
    10.1248/cpb.45.1631
  • 作为产物:
    描述:
    在 lithium hydroxide 作用下, 以 1,4-二氧六环 为溶剂, 反应 1.0h, 生成 {[N-methyl-N-(2-hydroxyethyl)amino]carbonyl}-L-phenylalanine
    参考文献:
    名称:
    Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability
    摘要:
    A series of renin inhibitors have been prepared and evaluated for their susceptibility to cleavage by the serine protease chymotrypsin. The compounds were designed by consideration of the structural requirements in the active-site region of renin and chymotrypsin. By systematic alteration of the P3 phenylalanine residue, compounds with varying degrees of renin inhibitory potency and chymotrypsin susceptibility were obtained. Selected analogues from this group were examined in vivo for both their hypotensive effects and metabolic patterns.
    DOI:
    10.1021/jm00120a006
点击查看最新优质反应信息

文献信息

  • Novel amino acid derivatives possessing renin-inhibitory activities
    申请人:Japan Tobacco Inc.
    公开号:EP0396065A1
    公开(公告)日:1990-11-07
    An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.
    通用公式的氨基酸生物: 其中R1为 其中,R10为较低的烷基基团,R"为 (其中R111为较低的烷基基团,n为1至5的整数)或者可以被羟基或甲基取代的较低烷基基团,或者R'°和R"与相邻的原子 结合在一起; R12为原子,CnH2n+1-O-CO-(n如上定义)或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-(n和R12如上定义)和吡啶基取代的较低烷基基团; X为-CH2-、-O-或-NH-,Y为-O-或-NH-;其中 (其中Z为-0-、-S-、-S(O)-、-S(O)2-、- -、-CH(OH)-, 或 a和b分别独立为1至4的整数,且a和b的总和不超过5); R2为可以被较低烷基基团取代的芳基烷基基团; R3为原子或较低烷基基团; R4为较低烷基基团; A为羟基,B为原子,或者A和B与相邻的原子结合在一起,描述了一种药学上可接受的酸盐或其。本发明的化合物具有对肾素的抑制活性,并可用作降压药。
  • Novel urea derivatives
    申请人:SANTEN PHARMACEUTICAL CO., LTD.
    公开号:US20020198376A1
    公开(公告)日:2002-12-26
    Objects of the present invention are to create compounds having urea structure as basic structure and having a sulfur atom and an amide bond in side chains and to find pharmacological effects thereof, particularly TNF-&agr; production inhibitory effects. The present invention provides compounds represented by the following formula [I] wherein R 1 is H, alkyl, aromatic, R A —CO—, R C —S— or the formula [II]; R 2 , R 3 and R 4 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R 5 and R 6 can together form a nonaromatic heterocyclic ring; R7 is H, alkyl, cycloalkyl, hydroxy, mercapto, phenyl, R B —O—, R C —S—, R D —COS—, R E —OCO—, R F —N(R G )— or —CONHOH; and A 1 and A 2 are alkylene. 1
    本发明的目的是创建具有尿素结构作为基本结构并在侧链中具有原子和酰胺键的化合物,并发现其药理作用,特别是TNF-α生产抑制作用。本发明提供由以下式子(I)表示的化合物,其中R1为H、烷基、芳香基、RA—CO—、RC—S—或式子(II);R2、R3和R4为H、烷基、基、环烷基、环基或芳香基;R5和R6为H、烷基、基、环烷基、环基或芳香基;R5和R6可以一起形成非芳香杂环;R7为H、烷基、环烷基、羟基、巯基、基、RB—O—、RC—S—、RD—COS—、RE—OCO—、RF—N(RG)—或—CONHOH;A1和A2为烷基。
  • NOVEL UREA DERIVATIVES
    申请人:SANTEN PHARMACEUTICAL CO., LTD.
    公开号:EP1072591A1
    公开(公告)日:2001-01-31
    Objects of the present invention are to create compounds having urea structure as basic structure and having a sulfur atom and an amide bond in side chains and to find pharmacological effects thereof, particularly TNF-α production inhibitory effects. The present invention provides compounds represented by the following formula [I] wherein R1 is H, alkyl, aromatic, RA-CO-, RC-S- or the formula [II]; R2, R3 and R4 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R5 and R6 are H, alkyl, alkenyl, cycloalkyl, cycloalkenyl or aromatic; R5 and R6 can together form a nonaromatic heterocyclic ring; R7 is H, alkyl, cycloalkyl, hydroxy, mercapto, phenyl, RB-O-, RC-S-, RD-COS-, RE-OCO-, RF-N(RG)- or ―CONHOH; and A1 and A2 are alkylene.
    本发明的目的是创造出以结构为基本结构、侧链中具有一个原子和一个酰胺键的化合物,并发现其药理作用,特别是抑制TNF-α产生的作用。 本发明提供了由下式[I]代表的化合物 其中 R1 是 H、烷基、芳香族、RA-CO-、RC-S- 或式[II];R2、R3 和 R4 是 H、烷基、基、环烷基、环基或芳香族;R5 和 R6 是 H、烷基、基、环烷基、环基或芳香族;R5 和 R6 可共同形成一个非芳香族杂环;R7 是 H、烷基、环烷基、羟基、巯基、基、RB-O-、RC-S-、RD-COS-、RE-OCO-、RF-N(RG)- 或 -CONHOH;以及 A1 和 A2 是亚烷基。
  • US6492370B1
    申请人:——
    公开号:US6492370B1
    公开(公告)日:2002-12-10
  • US6730784B2
    申请人:——
    公开号:US6730784B2
    公开(公告)日:2004-05-04
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸